Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis

Ai Kuzumi, Ayumi Yoshizaki, Kazuki M. Matsuda, Hirohito Kotani, Yuta Norimatsu, Maiko Fukayama, Satoshi Ebata, Takemichi Fukasawa, Asako Yoshizaki-Ogawa, Yoshihide Asano, Kyojiro Morikawa, Yutaka Kazoe, Kazuma Mawatari, Takehiko Kitamori & Shinichi Sato

Systemic sclerosis (SSc) is a chronic multisystem disorder characterized by fibrosis and autoimmunity. Interleukin (IL)-31 has been implicated in fibrosis and T helper (Th) 2 immune responses, both of which are characteristics of SSc. The exact role of IL-31 in SSc pathogenesis is unclear. Here we show the overexpression of IL-31 and IL-31 receptor A (IL-31RA) in dermal fibroblasts (DFs) from SSc patients. We elucidate the dual role of IL-31 in SSc, where IL-31 directly promotes collagen production in DFs and indirectly enhances Th2 immune responses by increasing pro-Th2 cytokine expression in DFs. Furthermore, blockade of IL-31 with anti-IL-31RA antibody significantly ameliorates fibrosis and Th2 polarization in a mouse model of SSc. Therefore, in addition to defining IL-31 as a mediator of fibrosis and Th2 immune responses in SSc, our study provides a rationale for targeting the IL-31/IL-31RA axis in the treatment of SSc.
Systemic sclerosis (SSc) is a connective tissue disease characterized by excessive extracellular matrix deposition of the skin and internal organs. The consequent fibrosis leads to tissue dysfunction and organ failure that can be debilitating and life threatening. Although the pathogenesis of SSc still remains unknown, various immunological abnormalities have been reported in SSc patients, indicating the autoimmune nature of the disease. In particular, activation and polarization of T cells have been extensively studied both in patients and in animal models of SSc.

For example, CD4+ T cells have been shown to infiltrate the lesional skin during the early stage of SSc. These tissue-infiltrating T cells show increased expression of activation markers. T cells in the peripheral blood have also been found to be activated in SSc. In addition, activated CD4+ T cells in SSc are predominantly skewed to T helper (Th) 2, which is implicated in tissue fibrosis. Indeed, major Th2 cytokines such as interleukin (IL)-4 and IL-13 are overexpressed in the skin and serum of SSc patients. Th2 cytokines are also associated with skin and lung fibrosis in bleomycin-induced SSc model (BLM-SSc) mice, a well-established experimental model of SSc.

Mechanistically, IL-4 and IL-13 directly induce collagen production in fibroblasts. Moreover, IL-4 drives the differentiation of naïve CD4+ T cells into IL-4-secreting Th2 cells, thus perpetuating the Th2 pro-fibrotic responses. Cytokines and chemokines that enhance Th2 immune responses also play important roles in SSc. For instance, IL-6, which is overexpressed in SSc patients, contributes to the development of SSc by driving Th2 differentiation as well as promoting collagen production in fibroblasts. Taken together, these studies suggest that Th2 dominance is a key immunological feature of SSc that directly and indirectly promotes fibrosis.

IL-31 is a member of IL-6 cytokine family that was originally described as an inducer of dermatitis in mice. IL-31 is mainly produced by Th2 cells and is expressed in a variety of cells, including fibroblasts, keratinocytes, and macrophages. Intracellular transmission of IL-31 signaling is mediated by a heterodimeric receptor consisting of IL-31 receptor A (IL-31RA) and oncostatin M receptor (OSMR). IL-31RA is unique to the IL-31 receptor family and is specifically expressed in activated T cells and keratinocytes. The activation of IL-31RA results in the expression of pro-inflammatory cytokines and chemokines, contributing to the pathogenesis of SSc.

**Fig. 1** Serum IL-31 levels correlated with fibrosis and Th2 polarization in SSc. a Serum IL-31 levels were determined in dcSSc patients (n = 55), lcSSc patients (n = 19), and healthy controls (n = 14) by a specific ELISA kit. The horizontal lines represent the mean values. The broken line represents the cut-off value (mean + 2 SD of the healthy controls). **p < 0.01 and ***p < 0.001 vs. healthy controls. Significance was evaluated by two-tailed Mann–Whitney U test. Exact p values = 0.00002 (SSc vs. Ctrl), 0.000008 (dcSSc vs. Ctrl), 0.008 (lcSSc vs. Ctrl). Ctrl; healthy controls. b Correlations between serum IL-31 levels and the following parameters were analyzed in SSc patients (n = 74): MRSS, %VC, %DLco, serum IL-4 levels, serum IL-6 levels, and serum IL-13 levels. Correlations were assessed by Spearman's rank correlation test. Exact p values = 0.000000005 (MRSS); 0.005 (%VC); 0.033 (%DLco); 0.012 (IL-4); 0.00003 (IL-6); 0.026 (IL-13). Source data are provided as a Source Data file.
Serum IL-31 levels correlate with fibrosis and its potential as a therapeutic target.

IL-31 has been closely associated with Th2-dominant diseases. Indeed, previous studies have shown increased expression of IL-31 in Th2-dominant diseases such as allergic asthma, atopic dermatitis, and cutaneous T-cell lymphoma, where IL-31 overexpression is associated with Th2 responses23-25. Of note, natalizumab, functionally blocking monoclonal antibody (mAb) against IL-31RA, has been shown to improve the skin manifestations of atopic dermatitis in a phase II trial, suggesting the potential of IL-31 as a therapeutic target31. In addition, recent studies have suggested the association of IL-31 with liver cirrhosis32. In the context of SSc, IL-31 expression is increased in fibrotic lungs of BLM-SSc mice33. Furthermore, Yaseen et al. have shown that IL-31 and IL-31RA are up-regulated in patients with SSC34. They have also demonstrated the pro-fibrotic effects of IL-31 in human dermal fibroblasts (DFs) and SSc model mice. These backgrounds led us to further explore the roles of IL-31 in SSc and its potential as a therapeutic target.

Here, we show that both IL-31 and IL-31RA are overexpressed in DFs from SSc patients and IL-31 promotes the expression of collagen and Th2-inducing cytokines. Moreover, we demonstrate that inhibiting IL-31 signaling by anti-IL-31RA mAb ameliorates fibrosis and Th2 polarization in BLM-SSc mice, providing a rationale for targeting IL-31 in the treatment of SSc.

Table 1 Clinical and laboratory features of SSc patients.

| Characteristic | Elevated IL-31 levels (n = 43) | Normal IL-31 levels (n = 31) |
|---------------|-------------------------------|-----------------------------|
| Sex, no. of women/men | 40/3 | 27/4 |
| Age at onset, median (quartiles) years | 44 (30–63) | 53 (38–67) |
| Disease duration, median (quartiles) years | 1 (0–4) | 1 (0–3) |
| Disease pattern, No. with | | |
| dCSSc/lCSSc | 39/4*** | 16/15 |
| MRSS, median (quartiles) points | 14 (10–20)*** | 8 (3–12) |
| Cutaneous vascular symptoms | | |
| Raynaud’s phenomenon | 93 | 90 |
| Nail fold bleeding | 67 | 52 |
| Telangiectasia | 53 | 45 |
| Pitting scars | 51 | 45 |
| Digital ulcers | 37 | 32 |
| Organ involvement | | |
| Pulmonary fibrosis | 84*** | 35 |
| %VC, median (quartiles) % | 81 (70–90)*** | 93 (78–104) |
| %DLco, median (quartiles) % | 74 (60–88)** | 88 (74–94) |
| Pulmonary hypertension | 5 | 6 |
| Esophagus | 86* | 65 |
| Kidneys | 5 | 0 |
| Laboratory features | | |
| IL-4, median (quartiles) pg/ml | 16.2 (13.4–19.8)** | 13.4 (11.0–14.7) |
| IL-6, median (quartiles) pg/ml | 6.13 (2.7–25.0)** | 2.50 (1.8–4.3) |
| IL-13, median (quartiles) pg/ml | 49.8 (42.2–65.3)* | 45.7 (31.2–53.8) |

Unless noted otherwise, values are in percentage. *p < 0.05, **p < 0.01, ***p < 0.001 vs. patient with SSc with normal serum IL-31 levels. Significance was determined by Fisher’s exact probability test for comparison of proportions and two-tailed Mann-Whitney U test for quantitative variables. Source data are provided as a Source Data file.

Results

Serum IL-31 levels correlate with fibrosis and Th2 polarization in SSc. Initially, we examined IL-31 levels in the sera of 74 SSc patients and 14 healthy controls by enzyme-linked immunosorbent assay (ELISA). Serum IL-31 levels were significantly elevated in SSc patients compared with healthy controls (Fig. 1a). Of note, circulating IL-31 was more abundant in diffuse cutaneous SSc (dcSSc) patients than in limited cutaneous SSc (lcSSc) patients. Next, SSc patients were classified into two groups according to the cut-off value of serum IL-31 levels set at 7.72 pg/ml (mean + 2 SD of healthy controls; Table 1). SSc patients with elevated serum IL-31 levels had higher frequencies of dcSSc, pulmonary fibrosis, and esophagus involvement, all of which are the clinical consequences of fibrosis, when compared to the patients with normal IL-31 levels. Indeed, SSc patients with elevated IL-31 levels were characterized by severe dermal and pulmonary fibrosis, with higher modified Rodnan total skin thickness score36 (MRSS) and lower percentage predicted values of vital capacity (%VC) and diffusing capacity for carbon monoxide (%DLco). In addition, SSc patients with elevated IL-31 levels had higher serum levels of IL-4, IL-6, and IL-13, the key cytokines associated with Th2 responses and overexpressed in SSc37. Consistently, serum IL-31 levels positively correlated with MRSS, negatively correlated with %VC and %DLco, and positively correlated with serum levels of IL-4, IL-6, and IL-13 (Fig. 1b). Thus, IL-31 overproduction in the sera of SSc patients correlated with fibrosis and Th2 up-regulation, the major features of the disease.

Both IL-31 and IL-31RA are overexpressed in SSc DFs. Next, we assessed mRNA levels of Il31 and Il31ra in the skin of 10 SSc patients and six healthy controls by real-time polymerase chain reaction (PCR). The SSc lesional skin showed significantly higher mRNA levels of Il31 and Il31ra compared with the skin of healthy controls (Fig. 2a). We next performed double-immunofluorescence staining to evaluate the expression and localization of IL-31 and IL-31RA protein in the SSc lesional skin (Fig. 2b). IL-31 and IL-31RA were colocalized with fibroblast-specific protein 1 (FSP-1), a fibroblast marker, in SSc lesional skin, indicating the expression of IL-31 and IL-31RA in SSc DFs. We did not detect colocalization of IL-31 or IL-31RA with FSP-1 in the skin of healthy controls. In SSc lesional skin, IL-31 was also colocalized with CD4 (Supplementary Fig. 1a), which is consistent with the previous studies showing IL-31 expression in Th2 cells19,20. Within the SSc subgroups, IL-31 and IL-31RA expression was significantly elevated at both mRNA and protein levels compared with DFs from healthy controls (Fig. 2c, d). Moreover, Il31 expression was enhanced by IL-4, and Il31ra expression was enhanced by IL-4 and IL-13 in SSc DFs (Fig. 2e), implying that Th2 dominance might contribute to the overexpression of IL-31 and IL-31RA in SSc DFs. We also detected the increased secretion of IL-31 from SSc DFs that were stimulated with IL-4 (Supplementary Fig. 2a). Collectively, both IL-31 and IL-31RA expression was up-regulated in SSc DFs, suggesting a role of the IL-31/IL-31RA axis in SSc fibrosis.

IL-31 promotes collagen and pro-Th2 cytokine production in SSc DFs. To investigate the role of IL-31 in SSc DFs, we subsequently stimulated DFs from SSc patients and healthy controls with recombinant human (rh) IL-31. In SSc DFs, rhIL-31 significantly and dose-dependently increased the mRNA levels of...
**Col1a1** and **Col1a2** (Fig. 3a), which encode type I collagen, the major extracellular matrix component of skin. By contrast, in healthy control DFs, the effect of rhIL-31 on collagen expression was modest, with **Col1a1** and **Col1a2** levels increased only when stimulated with a high concentration of rhIL-31 (100 ng/ml). Similarly, rhIL-31 enhanced type I collagen production from SSc DFs in a dose-dependent manner, whereas in healthy control DFs, type I collagen production was induced only at a high concentration of rhIL-31 (100 ng/ml; Fig. 3b). These results suggest that IL-31 is a direct inducer of collagen synthesis in SSc DFs, where IL-31RA is highly expressed. We also observed that the conditioned media of SSc DFs significantly increased the production of type I collagen in SSc DFs via IL-31 signaling (Supplementary Fig. 2b, c). Furthermore, rhIL-31 increased the expression of transforming growth factor (TGF)-β1 and decreased the expression of MMP-1, MMP-3, and MMP-9 in SSc DFs (Fig. 3c). Because TGF-β1 enhances collagen production in fibroblasts while MPPs promote its degradation, IL-31 might contribute to the cytokine environment that facilitates the excessive collagen deposition in SSc DFs. Stimulation with rhIL-31 also elevated the expression of α-smooth muscle actin (α-SMA) at both mRNA and protein levels (Fig. 3d, e), indicating that IL-31 promotes the transdifferentiation of SSc DFs to myofibroblasts. Moreover, rhIL-31 promoted proliferation and migration, and suppressed apoptosis of SSc DFs (Fig. 3f–h), thus enhancing the characteristic features of SSc DFs that contribute to

---

**Fig. 2** IL-31 and IL-31RA were up-regulated in skin and DFs of SSc patients. **a** Relative mRNA expression levels of **Il31** and **Il31ra** were analyzed by real-time PCR in the skin of SSc patients (n = 10) and healthy controls (n = 6). Exact p values = 0.0002 (**Il31**); 0.0002 (**Il31ra**). Relative fold differences = 2.37 (**Il31**); 3.89 (**Il31ra**). **b** Representative double-immunofluorescence images for IL-31 (top, red), IL-31RA (bottom, red), FSP-1 (green), and nuclei (DAPI, blue) in the skin of SSc patients and healthy controls (scale bar—20 µm). The results shown are representative of three independent experiments with similar results. **c, d** Relative mRNA levels (c) and protein levels (d) of IL-31 and IL-31RA in DFs from SSc patients and healthy controls (n = 7, respectively) were assessed by real-time PCR and ELISA, respectively. Exact p values = 0.007 (**Il31**); 0.0006 (**Il31ra**); 0.004 (**Il31**); 0.0006 (**Il31RA**). Relative fold differences = 2.05 (**Il31**); 3.13 (**Il31ra**). **e** Relative mRNA expression levels of **Il31** and **Il31ra** were examined by real-time PCR in SSc DFs stimulated with IL-4 or IL-13 (n = 5, respectively). Exact p values (IL-4 0.1 ng/ml vs. media, IL-4 1 ng/ml vs. media, IL-4 10 ng/ml vs. media, IL-13 0.1 ng/ml vs. media, IL-13 1 ng/ml vs. media, IL-13 10 ng/ml vs. media) = 0.841, 0.008, 0.008, 0.151, 0.841, 0.548 (**Il31**); 0.310, 0.008, 0.008, 0.999, 0.008, 0.008 (**Il31ra**). Relative fold differences (IL-4 0.1 ng/ml, IL-4 1 ng/ml, IL-4 10 ng/ml, IL-13 0.1 ng/ml, IL-13 1 ng/ml, IL-13 10 ng/ml) = 1.02, 2.92, 6.78, 1.13, 0.98, 1.08 (**Il31**); 1.16, 5.36, 13.91, 1.01, 3.15, 4.76 (**Il31ra**). Data are presented as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. healthy controls (a, c, and d) or media (e). Significance was determined by two-tailed Mann-Whitney U test. Ctrl, healthy controls. Source data are provided as a Source Data file.
the excessive fibrosis in SSc\textsuperscript{39}. Overall, IL-31 enhanced SSc-like phenotype as well as promoted collagen production in SSc DFs. Apart from the excessive collagen synthesis, SSc DFs are associated with distinct profiles of cytokines and chemokines that contribute to the immune abnormalities of the disease\textsuperscript{40–42}.

Therefore, to explore the effect of IL-31 on cytokine and chemokine expression in SSc DFs, we stimulated SSc DFs with rhIL-31 and evaluated the expression of the following cytokines that are expressed in DFs and drive Th2 immune responses: IL-6, IL-33, and CC chemokine ligand (CCL) \textsuperscript{240–42}. As shown in

\begin{itemize}
  \item \textbf{a} Ctrl SSc \textbf{b} Ctrl SSc \textbf{c} TGF-\beta1 CTGF MMP-1 MMP-3 MMP-9 \textbf{d} Media IL-31 kDa 48 \textbf{e} Media IL-31 \textbf{f} Media IL-31 \textbf{g} Media IL-31 \textbf{h} Media IL-31 \textbf{i} Media IL-31 \textbf{j} Media IL-31
\end{itemize}
**Fig. 3** IL-31 induced SSc-like phenotype in DFs. a, b DFs from dcsSc patients and healthy controls were cultured for 24 h with rhIL-31 (0, 10, 25, 50, or 100 ng/ml) to examine Col1a1 and Col1a2 mRNA expression (a) and type I collagen production (b) by real-time PCR and ELISA, respectively. Exact p values (Ctrl – IL-31 10 ng/ml vs. Ctrl, Ctrl – IL-31 25 ng/ml vs. Ctrl, Ctrl – IL-31 50 ng/ml vs. Ctrl, Ctrl – IL-31 100 ng/ml vs. Ctrl, SSc + IL-31 10 ng/ml vs. SSc, SSc + IL-31 25 ng/ml vs. SSc, SSc + IL-31 50 ng/ml vs. SSc, SSc + IL-31 100 ng/ml vs. SSc) = 0.690, 0.095, 0.056, 0.008, 0.032, 0.016, 0.008, 0.008 (Col1a1); 0.421, 0.421, 0.222, 0.016, 0.008, 0.008, 0.008, 0.008 (Col1a2); 0.508, 0.127, 0.841, 0.008, 0.008, 0.008, 0.008, 0.008 (Type I collagen). Relative fold differences (Ctrl + IL-31 10 ng/ml vs. Ctrl + IL-31 25 ng/ml vs. Ctrl + IL-31 50 ng/ml vs. Ctrl + IL-31 100 ng/ml vs. Ctrl, SSc + IL-31 10 ng/ml vs. SSc, SSc + IL-31 25 ng/ml vs. SSc, SSc + IL-31 50 ng/ml vs. SSc, SSc + IL-31 100 ng/ml vs. SSc) = 1.10, 1.16, 1.19, 1.53, 1.47, 2.10, 2.24, 2.71, 2.86 (Col1a1); 1.11, 1.10, 1.31, 1.83, 2.35, 2.54, 2.75, 3.25 (Col1a2). c Protein levels of TGF-β1, CTGF, MMP-1, MMP-3, and MMP-9 were assessed by ELISA in the supernatants of dcsSc DFs treated with or without rhIL-31 (50 ng/ml). Exact p values = 0.008 (TGF-β1), 0.587 (CTGF), 0.008 (MMP-1), 0.016 (MMP-3), 0.024 (MMP-9). d Representative western blot analysis of α-SMA in dcsSc DFs treated with or without rhIL-31 (50 ng/ml; left). Quantification of protein expression normalized to β-actin (right). Exact p value = 0.008. e Relative mRNA expression level of Acta2 was evaluated by real-time PCR in dcsSc DFs treated with or without rhIL-31 (50 ng/ml). Exact p value = 0.008. f Relative fold difference = 2.85. g BrdU incorporation was quantified by ELISA in dcsSc DFs treated with or without rhIL-31 (50 ng/ml). The absorbance at 450 nm was measured. Exact p value = 0.008. h Annexin-V+ and 7-AAD+ cells were considered late apoptotic cells, respectively (right). Exact p values (IL-31 vs. media) = 0.008 (early apoptosis); 0.008 (late apoptosis). i, j rhIL-31 significantly increased the expression of IL-6, IL-33, and CCL2 at both mRNA and protein levels in SSc DFs. Thus, IL-31 also promoted pro-Th2 cytokine expression in SSc DFs.

Subsequently, we explored the signaling pathways through which IL-31 exerts its effects on SSc DFs. Western blot analysis revealed that rhIL-31 induced the phosphorylation of STAT3 in SSc DFs (Fig. 4a, which is consistent with the findings of Yaseen et al. 34). Stimulation with rhIL-31 also induced the phosphorylation of STAT1 and STAT5 in SSc DFs (Fig. 4a), which is in accordance with the study by Yaseen et al. 34. Stimulation with rhIL-31 also induced the phosphorylation of STAT3, and is is significantly but to a lesser degree than STAT3. Because a previous study has demonstrated the phosphorylation of STAT3 in SSc DFs (Fig. 4a), which is in accordance with the study by Yaseen et al. 34. Stimulation with rhIL-31 also induced the phosphorylation of STAT3, and is is significantly but to a lesser degree than STAT3. Therefore, signaling through STAT3 seems to play an important role in the induction of collagen by IL-31. Overall, these results suggest that the effects of IL-31 on SSc DFs are mainly mediated by IL-31RA and STAT3.

IL-31 promotes skin and lung fibrosis in BLM-SSc mice. To investigate the effect of IL-31 on fibrosis in vivo, we subcutaneously injected BLM-SSc mice and PBS-treated control mice with recombinant mouse IL-31 (rmIL-31; Fig. 5a). Administration of rmIL-31 significantly exacerbated skin and lung fibrosis of BLM-SSc mice (Fig. 5b, c). Consistently, BLM-SSc mice treated with rmIL-31 showed significantly increased expression of Col1a1, Col1a2, and type I collagen, compared with BLM-SSc mice treated with sham (Fig. 5d, e). In PBS-treated control mice, rmIL-31 induced skin and lung fibrosis significantly but to a lesser extent compared with BLM-SSc mice. We also observed the up-regulation of both IL-31 and IL-31RA in the fibrotic skin and lungs of BLM-SSc mice compared with PBS-treated control mice (Fig. 5f and Supplementary Fig. 4). Therefore, potent induction of the skin and lung fibrosis by rmIL-31 in BLM-SSc mice may be attributed to the abundant expression of IL-31RA in these tissues. Next, we explored the cell types expressing IL-31 in lung tissue (Supplementary Fig. 5a). In BLM-SSc mice, Il31 was primarily expressed by fibroblasts, where the knock-down of IL-31 with siRNA decreased the release of type I collagen (Supplementary Fig. 5b). Therefore, the autocrine expression of IL-31 in fibroblasts might play an important role for the excessive collagen production in the lungs of BLM-SSc mice. Similar results were obtained with Il31ra, which was also primarily expressed by fibroblasts in the lungs of BLM-SSc mice and whose knock-down in fibroblasts decreased the collagen release (Supplementary Fig. 5c, d). These results indicate the functional relevance of IL-31 and IL-31RA expression by fibroblasts in the context of BLM-induced lung fibrosis.

Subsequently, the effect of rmIL-31 on cytokine production in the skin and lungs were examined by real-time PCR and ELISA.
Fig. 4 IL-31 exerted its effects through IL-31RA and STAT3. a Representative western blot analysis of STAT1, STAT3, STAT5 and their phosphorylated forms in dcSSc DFs treated with rhIL-31 (50 ng/ml; left). Quantification of protein expression normalized to β-actin (right). Exact p values (10 min vs. 0 min, 20 min vs. 0 min) = 0.008, 0.008 (pSTAT1/STAT1); 0.016, 0.040 (pSTAT5/STAT5). Relative fold differences (10 min, 20 min) = 3.63, 3.34 (pSTAT1/STAT1); 2.11, 7.23 (pSTAT3/STAT3); 1.36, 1.35 (pSTAT5/STAT5). 

b Representative ChIP assay on dcSSc DFs assessing the binding of phosphorylated STAT3 to the Col1a2 enhancer (left). Immunoprecipitated chromatin was analyzed by real-time PCR using specific primers for the HS4 region of the Col1a2 enhancer (right). Exact p value = 0.029. n = 4 biologically independent experiments.

c Protein levels of type I collagen, IL-6, IL-33, and CCL2 were evaluated by ELISA in the supernatants of dcSSc DFs that were transfected with IL-31RA siRNA and treated with rhIL-31 (50 ng/ml). Exact p values (media vs. IL-31 + Ctrl siRNA, media vs. IL-31 + IL-31RA siRNA, IL-31 + Ctrl siRNA vs. IL-31 + IL-31RA siRNA) = 0.00000009, 0.111, 0.000007 (Type I collagen); 0.0000009, 0.202, 0.000007 (IL-6); 0.002, 0.766, 0.005 (IL-33); 0.000003, 0.222, 0.000002 (CCL2). d Protein levels of Type I collagen were measured by ELISA in the supernatants of dcSSc DFs that were transfected with OSMR siRNA or treated with inhibitors for STAT1 (STAT1-I: Fludarabine; 50 μM), STAT3 (STAT3-I: Stattic; 5 μM), or STAT5 (STAT5-I: Cas 285986-31-4; 50 μM), followed by the treatment with rhIL-31 (50 ng/ml). Exact p values = 0.238 (IL-31 + OSMR siRNA vs. IL-31), 0.175 (IL-31 + STAT1-I vs. IL-31), 0.008 (IL-31 + STAT3-I vs. IL-31), 0.548 (IL-31 + STAT5-I vs. IL-31). n = 5 biologically independent experiments, unless otherwise noted. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001. Significance was determined using two-tailed Mann-Whitney U test (a, b, and d) and one-way analysis of variance followed by Tukey’s post hoc comparison test (c). pSTAT1, phosphorylated STAT1; pSTAT3, phosphorylated STAT3; pSTAT5, phosphorylated STAT5. Source data are provided as a Source Data file.
The expression of IL-4, IL-6, IL-10, IL-17A, tumor necrosis factor (TNF), TGF-β1, and interferon (IFN)-γ was significantly upregulated in the skin and lungs of BLM-SSc mice compared with PBS-treated control mice (Fig. 6a, b, Supplementary Fig. 6), as previously reported\(^{10}\). Administration of rmIL-31 further increased the expression levels of IL-4, IL-6, IL-10, and TGF-β1 in the skin and lungs of BLM-SSc mice, promoting the overexpression of Th2 and pro-fibrotic cytokines in these tissues. In contrast, the expression levels of the Th1 cytokine IFN-γ, the Th17 cytokine IL-17A, and TNF in BLM-SSc mice were not altered by rmIL-31. Therefore, IL-31 augmented BLM-induced fibrosis with increased expression of cytokines that are associated with fibrosis and Th2 responses.

To further explore whether and to what extent the pro-fibrotic effects of IL-31 in vivo are mediated by Th2 responses, we administered an anti-IL-4 receptor α (IL-4 RA) mAb to mice alongside with rmIL-31 and BLM. As shown in Supplementary Fig. 7a, b, anti-IL-4RA mAb significantly attenuated skin and lung fibrosis induced by rmIL-31. However, compared with mice treated with BLM and sham, those treated with BLM, rmIL-31, and anti-IL-4RA mAb showed increased fibrosis of skin and lung, indicating that the pro-fibrotic effects of IL-31 were reduced but not completely prevented by anti-IL-4RA mAb. Similarly, anti-
IL-31 promotes Th2 polarization in BLM-SSc mice. We next examined the effect of rmIL-31 on the differentiation of splenic T cells (Fig. 7a, Supplementary Fig. 11). BLM-SSc mice showed an increased frequency of Th2 and Th17 cells and a decreased frequency of Treg cells compared to PBS-treated control mice. Furthermore, the ratios of Th2/Th1, Th17/Treg, and Th2/Treg cells were increased in BLM-SSc mice, which is in accordance with the Th2 and Th17 polarization of SSc. Treatment with rmIL-31 further enhanced the increased Th2 cell frequency, Th2/Th1 ratio, and Th2/Treg ratio in BLM-SSc mice. Although rmIL-31 significantly increased the frequency of Th17 cells in BLM-SSc mice, it also increased the frequency of Treg cells. Thus, rmIL-31 had no statistically significant effect on the Th17/Treg ratio in BLM-SSc mice. In PBS-control mice, administration of rmIL-31 induced a statistically significant increase in Th2 cell frequency and a decrease in Treg cell frequency. Administration of rmIL-31 did not significantly change Th2/Th1 ratio or Th17/Treg ratio, but increased Th2/Treg ratio in PBS-control mice. Similar results were obtained on T cells in lung and lung-draining lymph nodes, where rmIL-31 increased the frequency of Th2 and Th17 cells, Th2/Th1 ratio, and Th2/Treg ratio in BLM-SSc mice (Fig. 7b, c). As for serum cytokine levels, rmIL-31 enhanced the overproduction of IL-4 and IL-6 in BLM-SSc mice (Fig. 7d). Thus, IL-31 promoted Th2 polarization in BLM-SSc mice. We also examined the effects of rmIL-31 on macrophage differentiation in spleen, where rmIL-31 did not significantly change M1 macrophage frequency, M2 macrophage frequency, or M2/M1 ratio (Supplementary Fig. 12).

Anti-IL-31RA mAb reduces fibrosis and Th2 polarization in BLM-SSc mice. To explore the role of IL-31 in the development of SSc, we assessed fibrosis and Th2 polarization of BLM-SSc mice treated with functionally blocking anti-IL-31RA mAb (NRA0404). We administered anti-IL-31RA mAb weekly along with daily injections of BLM for three weeks (Fig. 8a). Anti-IL-31RA mAb significantly reduced dermal thickness, lung fibrosis score, and collagen content in the skin and lungs of BLM-SSc mice compared with isotype control IgG (Fig. 8b–e). Furthermore, anti-IL-31RA mAb attenuated the expression of IL-4, IL-6, IL-10, and TGF-β that was up-regulated in the skin and lungs of BLM-SSc mice (Fig. 8f, Supplementary Fig. 13). Treatment with
anti-IL-31RA mAb also significantly reduced Th2 cell frequency, Th2/Th1 ratio, and Th2/Treg ratio, but not Th17/Treg ratio in spleen, lung, and lung-draining lymph nodes of BLM-SSc mice (Fig. 9a–c). Furthermore, overproduction of IL-4 and IL-6 in the sera of BLM-SSc mice was ameliorated by anti-IL-31RA mAb (Fig. 9d). Overall, anti-IL-31RA mAb significantly attenuated BLM-induced fibrosis and Th2 polarization.

**Discussion**

In this study, we showed the efficacy of anti-IL-31RA mAb in a murine model of SSc. Although previous studies have suggested pro-fibrotic effects of IL-31, the efficacy of anti-IL-31RA mAb has not been explored in SSc. Here, we initially demonstrated that serum IL-31 levels were significantly elevated in SSc patients (Fig. 1a). Of note, serum IL-31 levels positively correlated with the severity of skin and lung fibrosis and serum levels of IL-4, IL-6, and IL-13 (Fig. 1b and Table 1), which suggests the association of IL-31 with fibrosis and Th2 immune responses in SSc. Moreover, both IL-31 and IL-31RA expression was significantly increased in DFs from SSc patients compared with those from healthy controls (Fig. 2). In SSc DFs, IL-31 induced collagen production and the expression of cytokines that promote...
fibrosis and Th2 polarization (Fig. 3). Importantly, these effects were mainly mediated by IL-31RA and STAT3 (Fig. 4). In BLM-SSc mice, exogenous administration of rmIL-31 resulted in exacerbated skin and lung fibrosis, increased proportion of Th2 cells, and elevated expression of the cytokines associated with fibrosis and Th2 responses (Figs. 5–7). These results led us to propose that IL-31 augments fibrosis and Th2 polarization in SSc. Furthermore, anti-IL-31 mAb significantly attenuated fibrosis and Th2 polarization in BLM-SSc mice (Figs. 8, 9), demonstrating the crucial role of IL-31 in the development of SSc. Overall, in keeping with the recent analysis by Yaseen et al. 34, these results suggest that IL-31 is a promising therapeutic target for SSc.

Excessive extracellular matrix production by fibroblasts is an important pathological feature of SSc that leads to progressive fibrosis of the skin and internal organs. 45 Recently, Yaseen et al. have shown pro-fibrotic effects of IL-31 in both in vitro and in vivo. 46 Consistent with their results, we showed that IL-31 promoted excessive collagen production both in SSc DFs and BLM-SSc mice. Further, we also demonstrated that IL-31 promoted SSc-like phenotype in SSc DFs including increased differentiation to myofibroblasts (Fig. 3).

Th2 polarization is a major immunological abnormality in SSc that is observed both in the patients and animal models of SSc. 47 Accumulating evidence has shown that Th2 cells are the main producers of IL-31. 19,20,47 A recent study has also reported that IL-4 is essential for Th2 cells to secrete IL-31. 48 Together with the up-regulation of IL-31 and IL-31RA by Th2 cytokines (Fig. 2e), the overexpression of IL-31 in SSc patients presumably reflects the Th2 dominance of the disease. Furthermore, IL-31 enhanced the expression of IL-6, IL-33, and CCL2 in SSc DFs (Fig. 3i). Because these cytokines have been shown to promote Th2 cytokine expression in different cells and tissues, this result suggests that IL-31 promotes Th2 cytokine expression in SSc by up-regulating these pro-Th2 cytokines in DFs. 49–51 Indeed, in vivo studies showed that IL-31 promoted Th2 polarization in BLM-SSc mice (Figs. 6, 7). Since IL-31RA blocking mAb attenuated the expression of Th2 cytokines and the differentiation of Th2 cells in BLM-SSc mice (Figs. 8, 9), the results of this study indicate that IL-31 potentiates Th2 polarization in SSc.

SSc is one of the most devastating autoimmune diseases with high morbidity and mortality, which is largely attributed to the lack of effective treatment. Hence, developments of new drugs are highly desired in the treatment of SSc. The current study suggests that IL-31 contributes to the development of SSc in two ways: directly inducing collagen production in fibroblasts, and indirectly promoting Th2 polarization by inducing pro-Th2 cytokines in fibroblasts. Th2 polarization then further enhances IL-31 production, which forms a vicious cycle via the IL-31/IL-31RA axis, leading to the development of SSc. Although further studies are required to clarify the exact role of IL-31 in the pathogenesis of SSc, our study offered a previously unidentified insight into the role of IL-31 in SSc. Moreover, our study provides the evidence that anti-IL-31RA mAb significantly ameliorates fibrosis and Th2 polarization in an experimental model of SSc. These results may support the clinical translation of anti-IL-31RA mAb for the treatment of SSc patients.

Methods

Serum samples. Serum samples for ELISA to determine IL-4, IL-6, IL-13, and IL-31 levels were obtained from 74 Japanese SSc patients (67 women and seven men; mean ± SD age, 51 ± 17 years; disease duration, 2.0 ± 2.2 years). All patients fulfilled the ACR/EULAR classification criteria for SSc. Patients treated with corticosteroids or other immunosuppressants prior to their first visits were excluded. Disease duration was calculated as the interval from the onset of the first SSc clinical manifestations other than Raynaud’s phenomenon to serum sampling. Patients were categorized by LeRoy’s classification system. 52 55 SSc patients (49 women and six men; age, 50 ± 16 years; disease duration, 2.1 ± 2.2 years) and 19 kSSc patients (18 women and one man; age, 54 ± 19 years; disease duration, 1.6 ± 2.0 years). As controls, 14 age- and sex-matched healthy Japanese individuals were enrolled. The whole study was conducted in compliance with the Declaration of Helsinki and approved by the ethics committee of the University of Tokyo Graduate School of Medicine. Written informed consent was obtained from all participants.
Clinical assessment. Complete medical histories, physical examinations, and laboratory tests, including measurements of %VC and %DLco were performed in all patients. %VC values less than 80% and %DLco values less than 75% were considered abnormal. Skin thickness was assessed by MRSS. Organ involvement was defined as follows: pulmonary fibrosis = bibasilar fibrosis on chest radiograph and high-resolution computed tomography; pulmonary hypertension = right ventricular systolic pressure of 35 mmHg or more on echocardiogram; esophagus = distal esophageal hypomotility on barium-contrast radiography and gastroesophageal reflux disease detected at upper gastrointestinal endoscopy; kidneys = malignant hypertension and rapidly progressive renal failure.

Mice and experimental protocol. Wild-type C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and housed under controlled temperature (21 ± 1˚C) and relative humidity (60 ± 10%) with a 12/12 h dark/light cycle. BLM (Nippon Kayaku, Tokyo, Japan) was dissolved in PBS at a concentration of 1 mg/ml. To generate BLM-SSc mice, BLM was injected at a dose of 200 μg subcutaneously into the shaved backs of female mice with a 26-gauge needle daily. The mice treated with PBS instead of BLM were used as controls for BLM-SSc mice. To evaluate the effects of IL-31 on BLM-SSc mice, rmIL-31 (200 ng; Abcam, Cambridge, MA, USA) and BLM was injected subcutaneously daily for 2 weeks (day 1 to day 14). Saline was used as a sham for rmIL-31. To evaluate the
**Fig. 7** IL-31 enhanced Th2 polarization in BLM-SSc mice. a-e The frequencies of Th1, Th2, Th17, and Treg cells in BLM-SSc and PBS-treated control (PBS-Ctrl) mice treated with either rml-31 or sham were analyzed by flow cytometry in spleen (a), lung (b), and lung-draining lymph nodes (c). Exact p values (PBS-Ctrl + sham vs. PBS-Ctrl + IL-31, PBS-Ctrl + sham vs. BLM-SSc + sham, PBS-Ctrl + IL-31 vs. BLM-SSc + IL-31, PBS-Ctrl + IL-31 vs. BLM-SSc + sham, PBS-Ctrl + IL-31 vs. BLM-SSc + IL-31) = 0.960, 0.417, 0.996, 0.145, 0.841, 0.625 (Th1, spleen); 0.017, 0.0002, 0.000000000007, 0.342, 0.00000001, 0.0000003 (Th2, spleen); 0.795, 0.005, 0.0000006, 0.059, 0.000006, 0.041 (Th17, spleen); 0.001, 0.00000001, 0.0008, 0.002, 0.926, 0.0003 (Treg, spleen); 0.521, 0.005, 0.000002, 0.079, 0.0002, 0.043 (Th2/Treg ratio, spleen); 0.206, 0.0005, 0.0007, 0.003, 0.044, 0.521 (Th17/Treg ratio, spleen); 0.007, 0.011, 0.0000004, 0.996, 0.006, 0.004 (Th2/Treg ratio, spleen); 0.966, 0.932, 0.996, 0.999, 0.904, 0.849 (Th1, lung); 0.018, 0.0003, 0.000000002, 0.233, 0.000003, 0.000009 (Th2, lung); 0.633, 0.005, 0.000002, 0.059, 0.0002, 0.039 (Th1, lung); 0.005, 0.00000002, 0.0002, 0.0002, 0.050, 0.048 (Treg, lung); 0.031, 0.0007, 0.00000002, 0.264, 0.00002, 0.0007 (Th1/Treg ratio, lung); 0.363, 0.0002, 0.000003, 0.005, 0.00005, 0.125 (Th17/Treg ratio, lung); 0.034, 0.0002, 0.00000005, 0.082, 0.000004, 0.0005 (Th2/Treg ratio, lung); 0.939, 0.488, 0.961, 0.221, 0.719, 0.772 (Th1, lung-draining lymph nodes); 0.038, 0.000009, 0.000000000006, 0.002, 0.00000001, 0.00000003 (Th2, lung-draining lymph nodes); 0.839, 0.010, 0.000001, 0.051, 0.000005, 0.013 (Th17, lung-draining lymph nodes); 0.057, 0.00000001, 0.001, 0.00002, 0.230, 0.009 (Treg, lung-draining lymph nodes); 0.225, 0.0008, 0.00000005, 0.004, 0.00000006, 0.000003 (Th2/Treg ratio, lung-draining lymph nodes); 0.398, 0.0003, 0.000001, 0.0005, 0.000001, 0.244 (Th17/Treg ratio, lung-draining lymph nodes); 0.11, 0.00000007, 0.000000000007, 0.000002, 0.000000000002, 0.00000005 (Th2/Treg ratio, lung-draining lymph nodes). d Serum levels of IL-4 and IL-6 were assessed by ELISA. Exact p values (PBS-Ctrl + sham vs. PBS-Ctrl + IL-31, PBS-Ctrl + sham vs. BLM-SSc + sham, PBS-Ctrl + sham vs. BLM-SSc + IL-31, PBS-Ctrl + IL-31 vs. BLM-SSc + sham, PBS-Ctrl + IL-31 vs. BLM-SSc + IL-31) = 0.129, 0.001, 0.0000002, 0.103, 0.0001, 0.019 (IL-4); 0.085, 0.032, 0.000007, 0.954, 0.012, 0.033 (IL-6). n = 5. Data are shown as mean ± SD. **p < 0.05, ***p < 0.01, and ****p < 0.001. Significance was determined using one-way analysis of variance with variation followed by Tukey’s post hoc comparison test. The results shown are representative of three independent experiments with similar results. Source data are provided as a Source Data file.

**ELISA.** ELISA was performed to evaluate the protein expression in serum, tissue homogenates, cell lysates, and cell supernatants. Human samples were analyzed using the specific ELISA kits for IL-4 (D4050, R&D Systems), IL-6 (D6050, R&D Systems), IL-13 (D1300B, R&D Systems), TGF-β1 (DB100B, R&D Systems), CTGF (DY9190-05, R&D Systems), MMP-9 (DMP900, R&D Systems), IL-1α (J33D0B, R&D Systems), CCL2 (DCP00, R&D Systems), IL-1β (ab119596, abcam), MMP-1 (ab215083, abcam), IL-13RAB2 (ab133970, abcam), IL-6 (M6000B, R&D Systems), IL-10 (M1000B, R&D Systems), TNF (MTA00B, R&D Systems), TGF-β1 (MB1000B, R&D Systems), IFN-γ (MI100F0, R&D Systems), IL-1β (ab216167, abcam), CTGF (LS-F26141-L, LifeSpan Biosciences, Seattle, WA, USA), IL-1α (LS-F5987, LifeSpan Biosciences), IL-31RA (LS-F14320, LifeSpan Biosciences), and Tyrocollagen (NBP2-75822, Novus Biologicals, Littleton, CO, USA). To activate latent TGF-β1 to the immunoreactive form, acid activation and neutralization were performed before the assay of TGF-β1 as recommended by the manufacturer. All experiments were performed in accordance with the manufacturer’s instructions.

**Histological analysis.** Skin and lung tissues were formalin-fixed, embedded in paraffin, and stained with hematoxylin and eosin. Dermal thickness, defined as the distance between the epidermal-dermal junction and the dermal-adipose junction, was measured. The severity of lung fibrosis was semi-quantitatively assessed, as described by Ashcroft et al. Briefly, the grading criteria were as follows: grade 0 = normal lung; grade 1 = minimal fibrogenic thickening of alveolar or bronchiolar walls; grade 2 = moderate thickening of walls without obvious damage to lung architecture; grade 3 = increased fibrosis with definite damage to lung structure and formation of fibrous bands or small fibrous masses; grade 7 = severe distortion of the structure and large fibrous areas; and grade 8 = total fibrous obliteration of fields. Grades 2, 4, and 6 were used as intermediate pictures between the aforementioned criteria. Formalin-fixed, paraffin-embedded skin and lung tissues were also stained with Masson’s trichrome to evaluate the deposition of collagen. Each section was examined independently by two investigators (A.K. and A.Y.) in a blinded manner.

**Hydroxyproline assay.** The collagen content of skin and lung tissue in mice was determined by QuickZyme Total Collagen Assay (Q2B5OT0C1L, QuickZyme Biosciences, Leiden, The Netherlands) according to the manufacturer’s instructions. Total left lungs and 6-mm punch biopsy skin samples were used.

**RNA isolation and real-time PCR.** Total RNA was isolated from tissues and cells using RNeasy spin columns (Qiagen, Crawley, UK) and ISOGEN II (Nippon Gene, Toyama, Japan), respectively, according to the manufacturers’ instructions. Total RNA from each sample was reverse-transcribed to cDNA. Gene expression was quantified using SYBR green real-time PCR master mix (TOYOBO, Osaka, Japan) and analyzed on an ABI Prism 7000 sequence detector (Applied Biosystems, Foster City, CA, USA). To normalize the amounts of loaded cDNA, GAPDH was used as an internal control. Relative fold differences were calculated using the comparative Ct method. The sequences of the primers are described in Supplementary Table 1.
**Flow cytometry.** Single-cell suspensions from spleen and lung-draining lymph nodes were prepared by gentle teasing. Subsequently, erythrocytes in spleen cell suspensions were lysed with ammonium chloride (StemCell Technologies, Cambridge, MA, USA). Lung cell suspensions were prepared by incubating minced lung in RPMI1640 medium with Liberase TM and DNase I (Roche, Indianapolis, IN, USA) for 30 min, followed by the lysis of erythrocytes with ammonium chloride.

For detection of Th1, Th2, or Th17 cells, single-cell suspensions from spleen, lungs, and lung-draining lymph nodes were prepared at $2 \times 10^6$ /ml in RPMI 1640 medium and were stimulated with 25 ng/ml PMA (Adipogen, San Diego, CA, USA) and 1 mg/ml ionomycin (Sigma, St Louis, MO, USA) in the presence of 2 μM Monensin (Invitrogen, Carlsbad, CA, USA) for 6 h at 37 °C in 5% CO₂. Samples were then surface stained with anti-CD3-PE mAb and anti-CD4-FITC mAb.
**Fig. 8 Anti-IL-31RA antibody attenuated fibrosing of BLM-SSc mice.** a) BLM-SSc and PBS-treated control (PBS-Ctrl) mice were administered with anti-mouse IL-31RA antibody (αIL-31RA) antibody and isotype control IgG (iso) on days 1, 8, and 15, and sacrificed on day 22 for evaluation. b) Representative histological sections of the skin and lungs stained with hematoxylin and eosin (left) and Masson trichrome (right) were shown (horizontal scale bars=100 μm in skin; 20 μm in lung). Vertical bars with arrows represent dermal thickness. Dermal thickness and lung fibrosis score were assessed histologically. Exact p values (PBS-Ctrl + iso vs. BLM-SSc + iso, PBS-Ctrl + iso vs. BLM-SSc + αIL-31RA, BLM-SSC + iso vs. BLM-SSC + αIL-31RA) = 0.00004, 0.028, 0.004 (dermal thickness); 0.000002, 0.000002, 0.000004 (lung fibrosis score). c) Hydroxyproline contents in skin and lung samples. Exact p values (PBS-Ctrl + iso vs. BLM-SSC + iso, PBS-Ctrl + iso vs. BLM-SSC + αIL-31RA, BLM-SSC + iso vs. BLM-SSC + αIL-31RA) = 0.000005, 0.052, 0.003 (skin); 0.000004, 0.011, 0.012 (lung). d) mRNA expression levels of Col1α1 and Col1α2 in the skin and lungs were evaluated by real-time PCR. Exact p values (PBS-Ctrl + iso vs. BLM-SSC + iso, PBS-Ctrl + iso vs. BLM-SSC + αIL-31RA, BLM-SSC + iso vs. BLM-SSC + αIL-31RA) = 0.0000000003, 0.000009, 0.0000000002 (Col1α1, skin); 0.000000002, 0.005, 0.00000006 (Col1α2, skin); 0.00000004, 0.014, 0.000002 (Col1α2, lung); 0.000000002, 0.001, 0.00000005 (Col1α2, lung). Relative fold differences (BLM-SSC + iso, BLM-SSC + αIL-31RA) = 4.21, 2.00 (Col1α1, skin); 5.64, 2.27 (Col1α2, skin); 2.62, 1.50 (Col1α2, lung); 3.08, 1.86 (Col1α2, lung). e) Protein expression of type I collagen in the skin and lungs was evaluated by ELISA. Exact p values (PBS-Ctrl + iso vs. BLM-SSC + iso, PBS-Ctrl + iso vs. BLM-SSC + αIL-31RA, BLM-SSC + iso vs. BLM-SSC + αIL-31RA) = 0.000002, 0.021, 0.000007 (skin); 0.00000005, 0.026, 0.000002 (lung). f) The mRNA expression of Il4, Il6, Il17a, Tnf, Tgfb1, and Ifng in the skin and lungs of these mice was evaluated by real-time PCR. Exact p values (PBS-Ctrl + iso vs. BLM-SSC + iso, PBS-Ctrl + iso vs. BLM-SSC + αIL-31RA, BLM-SSC + iso vs. BLM-SSC + αIL-31RA) = 4.19, 2.83 (Il4, skin); 18.90, 10.01 (Il6, skin); 3.15, 4.38 (Il17a, skin); 2.57, 2.55 (Tnf, skin); 3.52, 2.14 (Tgfb1, skin); 4.51, 4.30 (Ifng, skin); 5.00, 3.01 (Il4, lung); 17.72, 8.92 (Il6, lung); 2.56, 1.50 (Il17a, lung); 7.20, 7.05 (Il17a, lung); 17.19, 2.19 (Tnf, lung); 4.14, 2.48 (Tgfb1, lung); 5.34, 5.44 (Ifng, lung). n = 5. Data are shown as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001. One-way analysis of variance followed by Tukey’s post hoc comparison test was used. The results shown are representative of three independent experiments with similar results. PBS-Ctrl, PBS-treated control; αIL-31RA, anti-mouse IL-31RA antibody; iso, isotype control IgG. Source data are provided as a Source Data file.
Density of the bands was quantified using ImageJ 1.53e software (National Institutes of Health).

RNA interference. Cells were transfected with IL-31 siRNA, IL-31RA siRNA, OSMR siRNA, or control scrambled siRNA (Santa Cruz Biotechnology) for 24 h using HiPerFect Transfection Reagent (Qiagen) according to the manufacturer’s protocol. Then the cells were serum starved for 24 h and used for further studies.

ChIP assay. ChIP assay was performed using EpiQuik ChIP kit (P-2002-3, Epi gentek, Farmingdale, NY, USA) according to the manufacturer’s instruction. Briefly, human DFs were cross-linked with 1% formaldehyde and the cross-linked chromatin was sonicated to an average size of 300–500 base pairs. Anti-phosphorylated STAT3 antibody (Santa Cruz Biotechnology) was used for immunoprecipitation with normal rabbit IgG (Santa Cruz Biotechnology) as the negative control. The immunoprecipitated chromatin was analyzed by agarose gel electrophoresis and quantitative real-time PCR using primers specific for the HS4 region: 5'- TTCACATGAGCATTTGAGTATTG -3' and 5'- TCGTCAGTGTGTAACCCTCATC -3'.

Statistical analysis. Data are expressed as means ± SD. Statistical analysis was performed by two-tailed Mann-Whitney U test for two-group comparison, Fisher’s exact probability test for frequency analysis, and Spearman’s rank correlation coefficient for clinical correlation. One-way analysis of variance followed by Tukey’s post hoc comparison test was used for multiple group comparison. P values less than 0.05 were considered significant. All analyses were performed using GraphPad Prism 7.03 (GraphPad Software, La Jolla, CA, USA).
Fig. 9 Anti-IL-31RA antibody attenuated Th2 polarization in BLM-SSc mice. a–c The frequencies of Th1, Th2, Th17, and Treg cells in BLM-SSc and PBS-treated control (PBS-Ctrl) mice administrated with anti-mouse IL-31RA antibody (αIL-31RA) or isotype control IgG (iso) were analyzed by flow cytometry in spleen (a), lung (b), and lung-draining lymph nodes (c). Exact p values (PBS-Ctrl + iso vs. BLM-SSc + iso, PBS-Ctrl + iso vs. BLM-SSc + αIL-31RA, BLM-SSc + iso vs. BLM-SSc + αIL-31RA) = 0.649, 0.769, 0.978 (Th1, spleen); 0.0006, 0.269, 0.010 (Th2, spleen); 0.010, 0.085, 0.463 (Th17, spleen); 0.021, 0.026, 0.994 (Treg, spleen); 0.006, 0.674, 0.027 (Th2/Th17 ratio, spleen); 0.005, 0.020, 0.712 (Th17/Treg ratio, spleen); 0.0002, 0.042, 0.19 (Th2/Treg ratio, spleen); 0.547, 0.830, 0.878 (Th1, lung); 0.000004, 0.032, 0.002 (Th2, lung); 0.002, 0.005, 0.768 (Th17, lung); 0.042, 0.040, 0.999 (Treg, lung); 0.00001, 0.052, 0.983 (Th2/Th17 ratio, lung); 0.006, 0.010, 0.957 (Th17/Treg ratio, lung); 0.0000003, 0.003, 0.00004 (Th2/Treg ratio, lung); 0.000004, 0.00005, 0.00001 (Th2, lung); 0.00000008, 0.0005, 0.00009 (IL-6); n = 5. Data are shown as mean ± SD. 

References

1. Gabrielli, A., Avvedimento, E. V. & Krieg, T. Scleroderma. Ne&l J. Med. 360, 1899–2003 (2009).

2. Yoshizaki, A. Pathogenic roles of B lymphocytes in systemic sclerosis. Rheumatol. Lett. 195, 76–82 (2018).

3. O’Reilly, S., Hügel, T. & van Laar, J. M. T cells in systemic sclerosis: a reappraisal. Rheumatology 51, 1540–1549 (2012).

4. Roum, A. D., Whiteside, T. L., Medger, T. A. J. & Rodnan, G. P. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 27, 645–653 (1984).

5. Kalogerou, A. et al. Early T cell activation in the skin from patients with progressive systemic sclerosis. J. Autoimmun. 24, 328–332 (1999).

6. Salmon-Ehr, V. et al. Expression of interleukin-4 in scleroderma skin and lung: correlation with disease activity. J. Autoimmun. 141, 858–866 (2018).

7. Reilly, S., Hügle, T. & van Laar, J. M. T cells in systemic sclerosis: a reappraisal. Arthritis Rheum. 56, 148–152 (2010).

8. Hasegawa, M., Fujimoto, M., Kikuchi, K. & Takehara, K. Elevated serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J. Invest. Dermatol. 112, 456–462 (1999).

9. Postlethwaite, A. E., Holness, M. A., Kati, H. & Raghov, R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J. Clin. Invest. 90, 1479–1485 (1992).

10. Lee, C. G. et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J. Exp. Med. 194, 809–821 (2001).

11. Kopf, M. et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362, 245–248 (1993).

12. Sato, S., Hasegawa, M. & Takehara, K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J. Invest. Dermatol. Sci. 27, 140–146 (2001).

13. Lee, C. G. et al. Interleukin-13 receptor A antibody for atopic dermatitis. N. Engl. J. Med. 376, 826–835 (2017).

14. Ming, D. et al. Elevated TGF-β1/IL-31 pathway is associated with the disease severity of hepatitis B virus-related liver cirrhosis. Viral Immunol. 28, 209–216 (2012).

15. Shi, K. et al. Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice. Respir. Physiol. Neurobiol. 190, 113–117 (2014).

16. Yasen, B. et al. Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatol. Med. 59, 2625–2636 (2020).

17. Clements, P. J. et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J. Rheumatol. 20, 1892–1896 (1993).

18. Chiu, S. et al. Connective tissue growth factor causes persistent proalpaha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. J. Cell Physiol. 203, 447–456 (2005).

Received: 14 June 2020; Accepted: 13 September 2021; Published online: 12 October 2021
37. Varga, J. et al. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem. J. 247, 597–604 (1987).
38. Tsou, P. S. et al. Lipoic acid plays a role in sclerodema: insights obtained from sclerodema dermal fibroblasts. Arthritis Res. Ther. 16, 411 (2014).
39. Bhattacharyya, S., Wei, J. & Varga, J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat. Rev. Rheumatol. 8, 42–54 (2011).
40. Khan, K. et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann. Rheum. Dis. 71, 1235–1242 (2012).
41. Manetti, M. et al. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann. Rheum. Dis. 69, 598–605 (2010).
42. Wu, M. et al. CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts. Arthritis Rheum. 69, 1871–1878 (2017).
43. Papaioannou, I. et al. STAT3 controls COL1A2 enhancer activation cooperatively with JunB, regulates type I collagen synthesis posttranscriptionally, and is essential for lung myofibroblast differentiation. Mol. Biol. Cell. 29, 84–95 (2018).
44. Taki, Z. et al. Pathogenic activation of mesenchymal stem cells is induced by the disease microenvironment in systemic sclerosis. Arthritis Rheum. 72, 1361–1374 (2020).
45. Yoshizaki, A. et al. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum. 63, 3086–3097 (2011).
46. Stott, B. et al. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J. Allergy Clin. Immunol. 132, 446–453 (2013).
47. van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 72, 1747–1753 (2013).
48. LeRoy, E. C. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15, 202–205 (1988).
49. Sato, S., Ihn, H., Kikuchi, K. & Takehara, K. Antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum. 37, 391–394 (1994).
50. Yoshizaki, A. et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am. J. Pathol. 172, 1650–1663 (2008).
51. Seebur, S. et al. A robust high throughput platform to generate functional recombinant monobloncl antibodies using rabbit B cells from peripheral blood. PLoS ONE 9, e86184 (2014).
52. Okamoto, Y. et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum. 64, 3726–3735 (2012).
53. Ashcroft, T., Simpson, J. M. & Timbrell, V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41, 467–470 (1988).
54. Moro, K., Ealey, K. N., Kabata, H. & Koyasu, S. Isolation and analysis of group 2 innate lymphoid cells in mice. Nat. Protoc. 10, 792–806 (2015).
55. Iwata, Y. et al. Increased serum pentraxin 3 in patients with systemic sclerosis. J. Rheumatol. 36, 978–983 (2009).
56. Huaxu, F., Liu, T., McGarry, B., Uilenbruch, M. & Phan, S. H. Dual roles of IL-4 in lung injury and fibrosis. J. Immunol. 170, 2083–2092 (2003).
57. Ekoti, I., Brattig, N. W., Liebau, E. & Breloer, M. Nematode-derived proteins suppress proliferation and cytokine production of antigen-specific T cells via induction of cell death. PLoS ONE 8, e68580 (2013).
58. Xue, M. et al. Autocrine actions of matrix metalloproteinase (MMP)-2 counter the effects of MMP-9 to promote survival and prevent terminal differentiation of cultured human keratinocytes. J. Invest. Dermatol. 128, 2676–2685 (2008).

Acknowledgements
The authors appreciate Maiko Enomoto, Mayumi Hanzawa, and Natsuko Watanabe for technical support. There was no specific funding for this work.

Author contributions
A.K., A.Y., and S.S. designed the study and wrote the manuscript. A.K., K.M.M., H.K., Y.N., M.F., S.E., T.F., A.Y.-O., and Y.A. acquired the data. A.K. and A.Y. analyzed the data. K. Morikawa, Y.K., K. Mawatari, and T.K. provided essential reagents and expertise. A.Y. and S.S. supervised the work.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-26099-w.

Correspondence and requests for materials should be addressed to Ayumi Yoshizaki or Shinichi Sato.

Peer review information Nature Communications thanks Richard Stratton, Georgina Xanthou and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021
